LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Malamati Kourti; Wen G. Jiang; Jun Cai (2017)
Publisher: Hindawi Limited
Journal: Oxidative Medicine and Cellular Longevity
Languages: English
Types: Review
Subjects: Cytology, Review Article, QH573-671, Article Subject, R1
Carbon monoxide (CO) has always been recognised as a toxic gas, due to its higher affinity for haemoglobin than oxygen.\ud However, biological studies have revealed an intriguing role for CO as an endogenous signalling molecule, a gasotransmitter. CO is\ud demonstrated to exertmany cellular activities including anti-inflammatory, antiapoptotic, and antiproliferative activities. In animal\ud studies, CO gas administration can prevent tissues from hypoxia or ischemic-reperfusion injury. As a result, there are a plethora\ud of reports dealing with the biological applications of CO and CO-releasing molecules (CORMs) in inflammatory and vascular\ud diseases. CORMs have already been tested as a therapeutic agent in clinical trials. More recently, an increased interest has been\ud drawn to CO’s potential use as an anticancer agent. In this review, we will aim to give an overview of the research focused on the\ud role of COand CORMs in different types of cancer and expand to the recent development of the next generation CORMs for clinical\ud application in cancer treatment.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [1] C. C. Roma˜o and H. L. A. Vieira, “Metal carbonyl prodrugs: CO delivery and beyond,” in Bioorganometallic Chemistry: Applications in Drug Discovery, Biocatalysis, and Imaging, pp. 165-202, Wiley-VCH, 2015.
    • [2] R. Foresti, M. G. Bani-Hani, and R. Motterlini, “Use of carbon monoxide as a therapeutic agent: promises and challenges,” Intensive Care Medicine, vol. 34, no. 4, pp. 649-658, 2008.
    • [3] F. Gullotta, A. Di Masi, and P. Ascenzi, “Carbon monoxide: an unusual drug,” IUBMB Life, vol. 64, no. 5, pp. 378-386, 2012.
    • [4] F. Zobi, “CO and CO-releasing molecules in medicinal chemistry,” Future Medicinal Chemistry, vol. 5, no. 2, pp. 175-188, 2013.
    • [5] R. Motterlini, B. E. Mann, and R. Foresti, “eThrapeutic applications of carbon monoxide-releasing molecules,” Expert Opinion on Investigational Drugs, vol. 14, no. 11, pp. 1305-1318, 2005.
    • [6] S. Hayashi, Y. Omata, H. Sakamoto et al., “Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene,” Gene, vol. 336, no. 2, pp. 241-250, 2004.
    • [7] R. Motterlini and L. E. Otterbein, “eTh therapeutic potential of carbon monoxide,” Nature Reviews Drug Discovery, vol. 9, no. 9, pp. 728-743, 2010.
    • [8] B. Wegiel, D. Gallo, E. Csizmadia et al., “Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth,” Cancer Research, vol. 73, no. 23, pp. 7009-7021, 2013.
    • [9] A. R. Marques, L. Kromer, D. J. Gallo et al., “Generation of carbon monoxide releasing molecules (CO-RMs) as drug candidates for the treatment of acute liver injury: targeting of CO-RMs to the liver,” Organometallics, vol. 31, no. 16, pp. 5810- 5822, 2012.
    • [10] C. C. Roma˜o, W. A. Bla¨ttler, J. D. Seixas, and G. J. L. Bernardes, “Developing drug molecules for therapy with carbon monoxide,” Chemical Society Reviews, vol. 41, no. 9, pp. 3571-3583, 2012.
    • [11] L. Lo Iacono, J. Boczkowski, R. Zini et al., “A carbon monoxidereleasing molecule (CORM-3) uncouples mitochondrial respiration and modulates the production of reactive oxygen species,” Free Radical Biology and Medicine, vol. 50, no. 11, pp. 1556-1564, 2011.
    • [12] R. Long, I. Salouage, A. Berdeaux, R. Motterlini, and D. Morin, “CORM-3, a water soluble CO-releasing molecule, uncouples mitochondrial respiration via interaction with the phosphate carrier,” Biochimica et Biophysica Acta-Bioenergetics, vol. 1837, no. 1, pp. 201-209, 2014.
    • [13] U. Schatzschneider, “Novel lead structures and activation mechanisms for CO-releasing molecules (CORMs),” British Journal of Pharmacology, vol. 172, no. 6, pp. 1638-1650, 2015.
    • [14] P. V. Simpson and U. Schatzschneider, “Release of bioactive molecules using metal complexes,” Inorganic Chemical Biology: Principles, Techniques and Applications, pp. 309-339, 2014.
    • [15] R. D. Rimmer, A. E. Pierri, and P. C. Ford, “Photochemically activated carbon monoxide release for biological targets. Toward developing air-stable photoCORMs labilized by visible light,” Coordination Chemistry Reviews, vol. 256, no. 15-16, pp. 1509-1519, 2012.
    • [16] E. Palao, T. Slanina, L. Muchova´, T. Sˇolomek, L. V´ıtek, and P. Kla´n, “Transition-metal-free CO-releasing BODIPY derivatives activatable by visible to NIR light as promising bioactive molecules,” Journal of the American Chemical Society, vol. 138, no. 1, pp. 126-133, 2016.
    • [17] B. E. Mann, “Carbon monoxide: an essential signalling molecule,” in Topics in Organometallic Chemistry, vol. 32, pp. 247- 285, 2010.
    • [18] A. Loboda, A. Jozkowicz, and J. Dulak, “HO-1/CO system in tumor growth, angiogenesis and metabolism-targeting HO-1 as an anti-tumor therapy,” Vascular Pharmacology, vol. 74, pp. 11-22, 2015.
    • [19] S. Ahmad, P. W. Hewett, T. Fujisawa et al., “Carbon monoxide inhibits sprouting angiogenesis and vascular endothelial growth factor receptor-2 phosphorylation,” rThombosis and Haemostasis, vol. 113, no. 2, pp. 329-337, 2015.
    • [20] G. Li Volti, D. Sacerdoti, B. Sangras et al., “Carbon monoxide signaling in promoting angiogenesis in human microvessel endothelial cells,” Antioxidants and Redox Signaling, vol. 7, no. 5-6, pp. 704-710, 2005.
    • [21] P. K. Chatterjee, “Physiological activities of carbon monoxidereleasing molecules: C¸a ira,” British Journal of Pharmacology, vol. 150, no. 8, pp. 961-962, 2007.
    • [22] A. Loboda, A. Jozkowicz, J. Dulak et al., “Carbon monoxide: pro- or anti-angiogenic agent? Comment on Ahmad et al. (Thromb Haemost 2015; 113: 329-337),” rhTombosis and Haemostasis, vol. 114, no. 2, pp. 432-433, 2015.
    • [23] W.-Y. Lee, Y.-C. Chen, C.-M. Shih et al., “eTh induction of heme oxygenase-1 suppresses heat shock protein 90 and the proliferation of human breast cancer cells through its byproduct carbon monoxide,” Toxicology and Applied Pharmacology, vol. 274, no. 1, pp. 55-62, 2014.
    • [24] S. J. Carrington, I. Chakraborty, and P. K. Mascharak, “Rapid CO release from a Mn(i) carbonyl complex derived from azopyridine upon exposure to visible light and its phototoxicity toward malignant cells,” Chemical Communications, vol. 49, no. 96, pp. 11254-11256, 2013.
    • [25] I. Chakraborty, S. J. Carrington, J. Hauser, S. R. J. Oliver, and P. K. Mascharak, “Rapid eradication of human breast cancer cells through trackable light-triggered CO delivery by mesoporous silica nanoparticles packed with a designed photoCORM,” Chemistry of Materials, vol. 27, no. 24, pp. 8387-8397, 2015.
    • [26] S. J. Carrington, I. Chakraborty, J. M. L. Bernard, and P. K. Mascharak, “Synthesis and characterization of a 'turn-on' photoCORM for trackable co delivery to biological targets,” ACS Medicinal Chemistry Letters, vol. 5, no. 12, pp. 1324-1328, 2014.
    • [27] E. U¨stu¨n, A. O¨ zgu¨r, K. A. Co¸skun, S. Demir, ˙I. O¨ zdemir, and Y. Tutar, “CO-releasing properties and anticancer activities of manganese complexes with imidazole/benzimidazole ligands,” Journal of Coordination Chemistry, vol. 69, no. 22, pp. 3384- 3394, 2016.
    • [28] C. S. Jackson, S. Schmitt, Q. P. Dou, and J. J. Kodanko, “Synthesis, characterization, and reactivity of the stable iron carbonyl complex [Fe(CO)(N4Py)](ClO4)2: photoactivated carbon monoxide release, growth inhibitory activity, and peptide ligation,” Inorganic Chemistry, vol. 50, no. 12, pp. 5336-5338, 2011.
    • [29] A. E. Pierri, A. Pallaoro, G. Wu, and P. C. Ford, “A luminescent and biocompatible photoCORM,” Journal of the American Chemical Society, vol. 134, no. 44, pp. 18197-18200, 2012.
    • [30] J. Niesel, A. Pinto, H. W. Peindy N'Dongo et al., “Photoinduced CO release, cellular uptake and cytotoxicity of a tris(pyrazolyl)methane (tpm) manganese tricarbonyl complex,” Chemical Communications, no. 15, pp. 1798-1800, 2008.
    • [31] N. E. Bru¨ckmann, M. Wahl, G. J. Reiß, M. Kohns, W. Wa¨tjen, and P. C. Kunz, “Polymer conjugates of photoinducible COreleasing molecules,” European Journal of Inorganic Chemistry, pp. 4571-4577, 2011.
    • [32] S. Hu, X. Cui, W. He et al., “Synthesis, structural characterization and preliminary biological studies of several heterocyclic transition metal carbonyl complexes,” Zeitschrift fur Anorganische und Allgemeine Chemie, vol. 641, no. 14, pp. 2452-2459, 2015.
    • [33] Y. Gong, T. Zhang, H. Liu et al., “Synthesis, toxicities and cell proliferation inhibition of CO-releasing molecules containing cobalt,” Transition Metal Chemistry, vol. 40, no. 4, pp. 413-426, 2015.
    • [34] L. V´ıtek, H. Gbelcova´, L. Muchova´ et al., “Antiproliferative eefcts of carbon monoxide on pancreatic cancer,” Digestive and Liver Disease, vol. 46, no. 4, pp. 369-375, 2014.
    • [35] C. I. Schwer, P. Stoll, S. Rospert et al., “Carbon monoxide releasing molecule-2 CORM-2 represses global protein synthesis by inhibition of eukaryotic elongation factor eEF2,” International Journal of Biochemistry and Cell Biology, vol. 45, no. 2, pp. 201- 212, 2013.
    • [36] M. Allanson and V. E. Reeve, “Carbon monoxide signalling reduces photocarcinogenesis in the hairless mouse,” Cancer Immunology, Immunotherapy, vol. 56, no. 11, pp. 1807-1815, 2007.
    • [37] A. Loureiro, G. J. L. Bernardes, U. Shimanovich et al., “Folic acid-tagged protein nanoemulsions loaded with CORM-2 enhance the survival of mice bearing subcutaneous A20 lymphoma tumors,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 11, no. 5, pp. 1077-1083, 2015.
    • [38] D. Schlawe, A. Majdalani, J. Velcicky et al., “Iron-containing nucleoside analogues with pronounced apoptosis-inducing activity,” Angewandte Chemie-International Edition, vol. 43, no. 13, pp. 1731-1734, 2004.
    • [39] P. Peng, C. Wang, Z. Shi et al., “Visible-light activatable organic CO-releasing molecules (PhotoCORMs) that simultaneously generate uflorophores,” Organic and Biomolecular Chemistry, vol. 11, no. 39, pp. 6671-6674, 2013.
    • [40] J. Boczkowski, J. J. Poderoso, and R. Motterlini, “CO-metal interaction: vital signaling from a lethal gas,” Trends in Biochemical Sciences, vol. 31, no. 11, pp. 614-621, 2006.
    • [41] N. Takano, T. Yamamoto, T. Adachi, and M. Suematsu, “Assessing a shift of glucose biotransformation by LC-MS/MS-based metabolome analysis in carbon monoxide-exposed cells,” in Oxygen Transport to Tissue XXXI, vol. 662 of Advances in Experimental Medicine and Biology, pp. 101-107, Springer, Berlin, Germany, 2010.
    • [42] H. Soni, G. Pandya, P. Patel, A. Acharya, M. Jain, and A. A. Mehta, “Beneficial eefcts of carbon monoxide-releasing molecule-2 (CORM-2) on acute doxorubicin cardiotoxicity in mice: role of oxidative stress and apoptosis,” Toxicology and Applied Pharmacology, vol. 253, no. 1, pp. 70-80, 2011.
    • [43] Y. Tayem, T. R. Johnson, B. E. Mann, C. J. Green, and R. Motterlini, “Protection against cisplatin-induced nephrotoxicity by a carbon monoxide-releasing molecule,” American Journal of Physiology-Renal Physiology, vol. 290, no. 4, pp. F789-F794, 2006.
    • [44] L. Tong, K. N. Yu, L. Bao, W. Wu, H. Wang, and W. Han, “Low concentration of exogenous carbon monoxide protects mammalian cells against proliferation induced by radiationinduced bystander eefct,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 759, pp. 9-15, 2014.
    • [45] Y. K. Choi, E. D. Por, Y.-G. Kwon, and Y.-M. Kim, “Regulation of ROS production and vascular function by carbon monoxide,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 794237, 17 pages, 2012.
    • [46] Y. K. Choi, C.-K. Kim, H. Lee et al., “Carbon monoxide promotes VEGF expression by increasing HIF-1 protein level via two distinct mechanisms, translational activation and stabilization of HIF-1 protein,” eTh Journal of Biological Chemistry , vol. 285, no. 42, pp. 32116-32125, 2010.
    • [47] S. Fayad-Kobeissi, J. Ratovonantenaina, H. Dabire´ et al., “Vascular and angiogenic activities of CORM-401, an oxidant-sensitive CO-releasing molecule,” Biochemical Pharmacology, vol. 102, pp. 64-77, 2016.
    • [48] J. Fang, H. Qin, H. Nakamura, K. Tsukigawa, T. Shin, and H. Maeda, “Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention eefct in solid tumors,” Cancer Science, vol. 103, no. 3, pp. 535-541, 2012.
    • [49] F. K. Johnson and R. A. Johnson, “Carbon monoxide promotes endothelium-dependent constriction of isolated gracilis muscle arterioles,” American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 285, no. 3, pp. R536-R541, 2003.
    • [50] A. Jo¨zkowicz, I. Huk, A. Nigisch et al., “Heme oxygenase and angiogenic activity of endothelial cells: stimulation by carbon monoxide and inhibition by tin protoporphyrin-IX,” Antioxidants and Redox Signaling, vol. 5, no. 2, pp. 155-162, 2003.
    • [51] J. Dulak, J. Deshane, A. Jozkowicz, and A. Agarwal, “Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis,” Circulation, vol. 117, no. 2, pp. 231-241, 2008.
    • [52] M. Ferrando, G. Gueron, B. Elguero et al., “Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer,” Angiogenesis, vol. 14, no. 4, pp. 467-479, 2011.
    • [53] K. Skrzypek, M. Tertil, S. Golda et al., “Interplay between heme oxygenase-1 and miR-378 aefcts non-small cell lung carcinoma growth, vascularization, and metastasis,” Antioxidants and Redox Signaling, vol. 19, no. 7, pp. 644-660, 2013.
    • [54] C.-W. Lin, S.-C. Shen, W.-C. Hou, L.-Y. Yang, and Y.-C. Chen, “Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9,” Molecular Cancer eThrapeutics , vol. 7, no. 5, pp. 1195-1206, 2008.
    • [55] X. Ji, K. Damera, Y. Zheng, B. Yu, L. E. Otterbein, and B. Wang, “Toward carbon monoxide-based therapeutics: critical drug delivery and developability issues,” Journal of Pharmaceutical Sciences, vol. 105, no. 2, pp. 406-415, 2016.
    • [56] S. Garc´ıa-Gallego and G. J. L. Bernardes, “Carbon-monoxidereleasing molecules for the delivery of therapeutic co in vivo,” Angewandte Chemie-International Edition, vol. 53, no. 37, pp. 9712-9721, 2014.
    • Volume 2014 Volume 2014
  • No similar publications.